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Background: International medical organizations such as the American Society of Medical Oncology recommend
early palliative care as the “gold standard” for palliative care in patients with advanced cancer. Nevertheless, even in
Comprehensive Cancer Centers, early palliative care is not yet routine practice. The main goal of the EVI project is
to evaluate whether early palliative care can be implemented—in the sense of “putting evidence into practice”—into
the everyday clinical practice of Comprehensive Cancer Centers. In addition, we are interested in (1) describing the
type of support that patients would like from palliative care, (2) gaining information about the effect of palliative care
on patients’ quality of life, and (3) understanding the economic burden of palliative care on patients and their families.
Methods/design: The EVI project is a multi-center, prospective cohort study with a sequential control group design.
The study is a project of the Palliative Care Center of Excellence (KOMPACT) in Baden-Württemberg, Germany, which
was recently established to combine the expertise of five academic, specialist palliative care departments. The study
is divided into two phases: preliminary phase (months 1–9) and main study phase (months 10–18). In each of all five
participating academic Comprehensive Cancer Centers, an experienced palliative care physician will be hired for
18 months. During the preliminary phase, the physician will be allowed time to establish the necessary structures for
early palliative care within the Comprehensive Cancer Center. In the main study phase, patients with metastatic
cancer will be offered a consultation with the palliative care physician within eight weeks of diagnosis. After the initial
consultation, follow-up consultations will be offered as needed. The study is built upon a convergent parallel design.
In the quantitative arm, patients will be surveyed in both the preliminary and main study phase at three points in time
(baseline, 12 weeks, 24 weeks). Standardized questionnaires will be used to measure patients’ quality of life, symptom
burden and mood. Using interviews with palliative care physicians, oncologists, department heads, patients and their
caregivers, the qualitative arm will explore (1) what factors encourage and hinder the early integration of palliative care
into standard oncology care, (2) what support patients and their caregivers would like from palliative care, and (3) what
effect palliative care has on the economic disease burden of patients and their families.
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Discussion: The study proposed is meant to serve as a catalyzer. Local palliative care teams should be put in position
to routinely cooperate with the primary treating department at their respective cancer center. The long-term goal of
this project is to create sustainable improvements in the care of patients with incurable cancer.
Trial registration: DRKS00006162; date of registration: 19/05/2014
Keywords: Cancer, Terminally ill patients, Early palliative careBackground
The primary goal of palliative care (PC) is to ensure
quality of life (QoL) for patients with incurable, life-
limiting diseases and their caregivers. This is true for all
patients, regardless of their disease (e.g. amyotrophic
lateral sclerosis, multiple sclerosis, heart failure, chronic
obstructive pulmonary disorder, etc.) However, patients
with incurable cancer remain one of the largest patient
groups with a need for palliative care [1]. Due to the
continuing advances in cancer treatment, cancer is
likely to increasingly become a chronic disease [2].
In the past and even today, PC has often been falsely
equated with end-of-life care [3]. For this reason, treatment
goals in standard oncology care have often focused solely
on prolonging life rather than improving QoL early in the
course of the disease [4]. Even in early stages of the disease,
patients with incurable cancer often suffer from multiple
physically burdensome symptoms (e.g. pain) [5] and
psychosocial and spiritual anxiety. By focusing on life-
prolonging treatment options, the suffering that patients
and their families experience from these symptoms often
goes unnoticed and is not adequately relieved [3]. The
outdated dictum “first prolong life, then improve quality
of life” should be replaced by a holistic, integrative model
[6]. This approach is referred to as early palliative care
(EPC). According to this model, specialist palliative care
expertise focused on the needs of the patient should
be offered alongside standard oncology care [7].
For patients with non-small cell lung cancer (NSCLC),
Temel et al. [8] showed that EPC improved patients’
QoL, reduced the incidence of depression, and decreased
the number of aggressive (and generally futile) therapies
at the end of life. In addition, EPC increased patients’
survival time [8]. In a randomized study with patients
suffering from different cancer entities, Zimmermann et al.
[9] found that patients who received EPC not only had a
better QoL but also a higher level of satisfaction with their
treatment compared to those in the control group, who
were not offered EPC.
Meanwhile, international medical organizations such
as the American Society of Medical Oncology (ASCO)
have recommended EPC as the “gold standard” for
palliative care in patients with advanced cancer [3]. How-
ever, integrating palliative care into standard oncology care
early in the course of the disease requires a reorientationand restructuring of current medical practice. For this
reason, EPC has not yet become a routine part of care
even in Comprehensive Cancer Centers (CCCs) [3].
In spite of their clear recommendation for EPC, the
National Cancer Institute and the ASCO also point
out that there are considerable deficits in the currently
available publications on EPC [3]. These institutions
criticize that studies have focused on limited patient popu-
lations (e.g. patients with NSCLC) rather than the entire
spectrum of cancer patients who are actually treated
in CCCs. Furthermore, recent studies have been criticized
because they have been conducted under ideal circum-
stances, which do not correspond to the real-life situation.
This makes it impossible to assess the feasibility and
effectiveness of EPC in the actual clinical setting [10].
Until now, there has been a lack of research investigating
the implementation of EPC into everyday clinical practice,
using the already available resources and structures
[11]. In light of this, the study proposed here aims to
implement EPC into clinical practice at all five CCCs
throughout the federal state of Baden-Württemberg,
Germany. The study is a project of the Palliative Care
Center of Excellence (KOMPACT) in Baden-Württemberg,
Germany. It is funded by the Robert Bosch Foundation
who has formally peer reviewed our study protocol before
assigning the grant. Patients with advanced metastatic
cancer that is unresponsive to curative treatments will
routinely be offered palliative care as soon as possible after
diagnosis, according to the most up-to-date international
treatment standards.
The main goal of the EVI project is to evaluate
whether EPC can be implemented into the everyday
clinical practice of CCCs, and if so, what conditions are
necessary for it to succeed. In addition, we are interested in
(1) describing the type of support that patients would like
from palliative care, (2) gaining information about the effect
of palliative care on patients’ QoL and healthcare costs, and
(3) determining which factors could potentially encourage
or hinder the implementation of EPC, respectively.
Methods/design
The design of the study
In the field of PC, conducting clinical studies is associated
with considerable challenges. Reasons for this include (1)
a lack of established scientific standards for PC research
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situation of PC patients, which places unique demands on
the design of studies with this patient population [12].
Only recently was a guidance statement for end-of-life
care research developed in the context of the “Methods of
Researching End of Life Care” (MOREcare) project, which
expanded on the Medical Research Council guidance on
the development and evaluation of complex circumstances
[13]. The design of the study proposed here closely follows
the guidelines established by the MOREcare project.
Another important underlying premise of our project
is its real-world design, which involves the routine
implementation of EPC in the clinical setting and
helps avoid artificial study conditions.
The study is divided into two phases: preliminary phase
(months 1–9) and main study phase (months 10–18). In
each of the five participating CCCs, an experienced pallia-
tive care physician will be hired for 18 months with a 50 %
position. During the preliminary phase of the study, the
physician will be allowed time to establish the necessary
structures for EPC within the clinic. In addition, patients
will also be recruited during this phase to establish a
reference group for comparison between the status quo
and those in the main study phase who receive EPC.
In the main study phase, patients with metastatic cancer
will routinely be offered a consultation with the PC
physician within eight weeks of diagnosis. This initial
consultation has multiple objectives. First, this meeting
serves to provide information regarding the value and
accessibility of specialist palliative care. The PC physician
will explain to patients that interdisciplinary cancer treat-
ment ensures that all meaningful treatment options will
continue to be available (“fight against cancer”) but that
high priority will be placed on QoL also. For QoL needs,
specialist palliative care services will be available to
patients alongside treatment from the primary cancer
specialist. It is important to make clear to patients
that EPC is supplementary to standard oncology care
and aims at supporting the treating cancer specialist.
The cancer specialist will remain the primary contact
person regarding patients’ treatment options.
The second main objective of the initial consultation is
to create a certain familiarity with palliative care, which
will help reduce barriers to accessing these services in
the future.
In the initial consultation, a detailed assessment of
patients’ physical symptoms (e.g. pain), psychosocial issues,
spiritual burden and information needs will be conducted
using a combination of both structured and unstruc-
tured methods. If an intervention appears necessary
(e.g. adjusting medications), suggestions will be provided
to the primary treating physician and, when possible, will
be carried out directly in the outpatient clinic of the CCC.
In these cases, a follow-up consultation will be arrangedbetween the patient and PC physician. Otherwise, patients
and treating physicians have the possibility to contact the
PC physician as necessary. Follow-up consultations are
therefore not obligatory. Rather, additional meetings will
take place as needed, according to the requests of patients,
family members/caregivers or the treating physician.
In order to ensure that the EPC services in all five
CCCs are comparable, the palliative care physicians will
receive a special structured training during the preliminary
phase of the study. In an earlier project, a leading re-
searcher from our working group established which factors
are important for the early implementation of palliative
care [7]. Based on this, a method was developed to
improve physicians understanding of the initial PC
consultation and cooperation between various medical
specialties [14]. This method will serve as the basis of
our training for PC physicians in this study.
Before the main study phase begins, cancer specialists at
each center will be comprehensively informed about the
possibilities of EPC so that they are able to prepare
patients for the PC consultation. We will spread informa-
tion about EPC by distributing informational brochures,
sending a regular newsletter to physicians and nurses, and
by holding presentations to the tumor boards of each
participating center.
To evaluate the feasibility of the routine implementation
of EPC in CCCs, the study is built upon a convergent
parallel design [15]. The quantitative arm is conceived as a
multi-center, prospective cohort study with a sequential
control group design. Both in the preliminary and main
study phase, patients will be surveyed at three points in
time (baseline, 12 weeks, 24 weeks). Standardized ques-
tionnaires will be used to measure patients’ QoL, symptom
burden and mood. The economic effects of EPC will be
measured using an expense log or cost diary.
In light of the objective to test the feasibility of EPC,
the qualitative arm of the study consist of four interview
studies with palliative care physicians, oncologists/
department heads, patients and their families/caregivers.
These interviews will explore: (1) which factors encourage
and hinder the early integration of palliative care into
standard oncology care and (2) what support patients and
their families would like from palliative care and to what
extent these needs can be met through the EPC approach
used in this study.
After conclusion of the study, the results of the quantita-
tive and qualitative arms will be synthesized and evaluated
with regard to the feasibility of EPC in CCCs.
Quantitative arm
Participants
The EPC services provided in this study are aimed at
patients with advanced metastatic cancer that is unre-
sponsive to curative treatments (ICD 10 C 1–80 plus
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will be identified in the tumor boards of each center.
As soon as the diagnostic process has been concluded
and treatment has started (i.e. within the first eight
weeks after diagnosis), patients will be referred to the PC
physician. Table 1 shows the inclusion and exclusion
criteria for participation.
Outcome assessment
We will consider EPC to be feasible if 75 % of all eligible
patients (i.e. adult patients diagnosed with an incurable,
metastatic cancer [ICD 10 C 1–80 plus ICD 10 C 78–79])
are referred to a PC physician at their center at least once
within eight weeks of the initial diagnosis.
Patients’ QoL and symptom burden will be assessed at
the initial PC consultation using the “Palliative Outcome
Scale” (POS) [16], the “European Organization for Research
and Treatment of Cancer (EORTC) QLQ-C30” [17], and
the “Hospital Anxiety and Depression Scale” (HADS)
[18]. Both in the preliminary and the main study phase, a
follow-up assessment will be conducted at 12 and
24 weeks using these three instruments. Family/caregivers
of the patient will be asked to assess the patients’
situation by filling out the “Quality of Dying and Death”
questionnaire [19].Table 1 Inclusion and exclusion criteria for participation in the
quantitative study arm
Inclusion criteria:
1. Initial diagnosis of a metastatic, incurable cancer (ICD 10 C 1–80 plus
ICD 10 C 78–79) occurred within the last eight weeks, particularly:
- non-small cell lung cancer (NSCLC) without epidermal growth
factor (EFGR) mutations: met. NSCLC Stage IV – ICD C34.[01239] +
metastasis code or C34.8 (multiple subdomains) + possibly M8012/3
(large cell carcinoma)
- met. esophageal carcinoma Stage IV – ICD C15.[123459] +
metastasis code or C15.8 (multiple subdomains) + possibly M8070/3
(squamous cell carcinoma)
- met. stomach carcinoma Stage IV - ICD C16.[01234569] +
metastasis code or C16.8 (multiple subdomains) + possibly
M8145/3 (adenocarcinoma, diffuse)
- non-endocrine pancreas carcinoma Stage IV - ICD C25.[012379] +
metastasis code or C25.8 (multiple subdomains) + possibly M8971/3
(pancreas blastoma)
- center-specific tumor entities
2. Age ≥ 18 years
3. Ability to understand written and verbal questions in German
4. Willingness to participate in the study
5. Informed consent
Exclusion criteria:
1. Other hemato-oncological disease (e.g. leukemia)
2. Dementia
3. Psychosis/delirium
4. Major depressionThe effects of EPC on healthcare costs will be mea-
sured in part by the number of follow-up visits a patient
requires after the initial PC consultation, as recorded by
the PC physician. In addition, patients will be asked to
keep track of any additional costs in an expense log/cost
diary. The expense log/cost diary is a bottom-up approach
to understand direct and indirect costs of care from a
patient perspective and a societal perspective. It will
allow us to follow which kind of health-related services/
treatments are used including services not reimbursed by
the Statutory Health Insurance, how much productivity of
patients and caregivers is lost and how much patients
and their families spend on out-of-pocket payments.
Accordingly, patients and their caregivers will be instructed
to quantify all health-related costs and the reason for the
costs in a provided expense log/cost diary. The expense
log/cost diary will be developed based on a literature
review and interviews with patients and their families. It
will be pretested extensively before routine use.
Quantitative data collection in the preliminary and main
study phase
In each participating CCC, a study coordinator will be
appointed. As soon as a patient is identified in the tumor
board as a potential participant, the study coordinator will
contact the patient, provide the patient with information
and ask for the patient’s consent to participate in the
study. If the patient is willing to participate, the study
coordinator will explain the expense log/cost diary
and hand it out to the patient. He will also ask the patient
to fill out the T0-questionnaires. The T0-questionnaires
(i.e. POS, EORTC, QLQ-C30 and HADS) will be added
to the patient file and will therefore be accessible to
the treating physician. After 12 weeks, the patient will
be contacted again by the study coordinator and will
be asked to complete the T1-questionnaires. At the
same time, the study coordinator will remind the patient
to regularly fill out the expense log. A second follow-up
assessment will occur at 24 weeks, and the patient
will be asked to complete the T2-questionnaires.
Also, the patient will be asked to return the completed
expense log.
The patient burden in the last days of life will be
assessed externally by a family member or most rele-
vant caregiver of the patient. After the patient’s death,
the family member/caregiver will be contacted and
asked to complete the “Quality of Dying and Death”
questionnaire via telephone. If the patient has not
died by the end of the study phase, this questionnaire
will not be filled out.
The following figures show the course of events
for both quantitative arms and the timeline for data
collection for the quantitative and qualitative arms
(Figs. 1 and 2).
Fig. 1 Course of events for both quantitative arms
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To judge the feasibility of the routine integration of
EPC into clinical practice at CCCs, we will measure
how many eligible patients were referred to the center’s
PC physician within the first eight weeks after diag-
nosis. For this, we will rely on the internal records of
the participating centers.
With an expected response rate of ca. 50 %, we aim
for a sample size of 1000 patients (200 per participating
CCC) in the preliminary study phase and an additional
1000 patients (200 per participating CCC) in the main
study phase. Differences between the control group
(patients in the preliminary study phase) and the
intervention group (patients in the main study phase)
will be analyzed with respect to symptom burden, QoL,
and mood. The longitudinal data (i.e. at 12 and 24 weeks)
will be analyzed in regard to changes between the baseline
measurement and follow-up measurements. Effect sizes
between 0.20 and 0.49 will be judged as small, between
0.50 and 0.79 as medium, and above 0.80 as large [20].
We will use descriptive data analysis along with t-tests,
chi-square tests, Mann–Whitney-U tests, and multi-
variate linear and binary logistical regression models.
All statistical tests will be two-sided, and p-value ≤ 0.05
will be considered significant. IMB SPSS (Version 21.0)
will be used to conduct data analysis.The qualitative arm
Participants and sampling
The qualitative arm of the EVI project consists of four inter-
view studies (Table 2). Interview partners for each study will
be recruited equally from each participating CCC.
Interview study with PC physicians The five PC physi-
cians hired for the project will be interviewed both in the
preliminary and main study phase regarding the feasibility
of integrating EPC into standard oncology care. In addition,
the PC physicians will be asked what factors support and
hinder the process of establishing EPC in their respective
center.
Interview study with oncologists and department
heads During the preliminary and the main study phase,
we will conduct expert interviews with 25 oncologists
and 25 department heads. The focus of these interviews
will be the feasibility of the routine integration of EPC
into standard oncology care. The sample of oncologists
and department heads will be achieved by using maximum
variation sampling.
Interview study with patients and family/caregivers
During the preliminary and the main study phase, 25
patients and 25 family members/caregivers will be
Fig. 2 Timeline of data collection
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like from palliative care in addition to standard oncology
care and how they perceive the provided EPC. The patient
and caregiver samples will also be achieved by using
maximum variation sampling. All patients and caregivers
will be recruited from the quantitative arm of the study.
In total, we aim at 210 interviews for the qualitative
arm of the project.
Outcome assessment
To adequately assess the feasibility of integrating EPC
into standard oncology care, it would be insufficient to only
measure whether 75 % of all eligible patients are referredTable 2 Planned qualitative interviews at each participating CCC





Palliative care physicians 1 1
Oncologists 5 5
Department heads 5 5
Patients 5 5
Family/caregivers 5 5
Total 21 21to a PC physician. Rather, it is essential to evaluate what
circumstances make it possible (or not) to implement
EPC. For this reason, the qualitative arm of this study will
assess the strengths and weaknesses of this model of EPC
along with potential areas of improvement from the
perspective of all stakeholders (PC physicians, oncologists/
department heads, patients and caregivers).Qualitative data collection in the preliminary and main
study phase
The responsible research assistants from the Department
of Palliative Care in Freiburg will work in close cooper-
ation with the PC physician at each CCC to coordinate
logistics and dates for the interviews in each of the four
interview studies. The interviews will be conducted by
interviewers who have received a training in qualitative
interview methods.Qualitative data analysis
The guided interviews will be analyzed after transcription
using the principles of qualitative content analysis. A team
of researchers will inductively develop a category system
in order to create a subject matrix for each of the four
interview studies [21]. Content analysis will be aided by
the use of the software program MAXQDA.
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The study has been designed according to the Declaration
of Helsinki [22]. The study protocol was approved by the
Ethics Committee of the University of Freiburg, Germany
(vote: 193/14, date: 25 April 2014) and the responsible
data protection officer. In addition, ethical approval was
obtained from the Ethics Committee of the University
of Tuebingen, the Ethics Committee of the Mannheim
University Hospital, the Ethics Committee of the University
Medical Center Heidelberg, and the Ethics Committee of
the University of Ulm. Consistent with good clinical prac-
tice, patients will be informed about participation in the
study, its implications and written consent will be obtained.
Discussion
The primary objectives of the implementation of EPC in
our study are (1) to identify patients with unmet palliative
care needs, (2) to advise patients regarding the possibilities
of specialized PC in their particular situation, (3) to reduce
inhibitions to make use of palliative care as a normal part
of the center’s treatment options, (4) to create a “double
awareness” for the will to survive (“fight against cancer”)
and inevitable mortality, and (5) to prevent that PC is
misunderstood as only end-of-life care.
Concerns have repeatedly been raised that cancer
treatment will become disintegrated if treatment is too
interdisciplinary [23]. Therefore, EPC must occur in close
cooperation and communication with all other responsible
departments (e.g. the oncology department). Above all, it
is important that the patient maintains a feeling of security
and does not become confused by conflicting messages
regarding prognosis and treatment goals. Patients and
their family/caregivers must always be aware who is
primarily responsible for their care (typically this will
be a physician from the oncology, radiation therapy or
senology department) [11]. The model of EPC imple-
mented in this study takes this premise very seriously.
Based on clinical and administrational experiences from
our EPC pilot study [7], we are convinced that EPC can
only be successfully integrated into standard oncology
care when there is close cooperation between PC and
cancer specialists [24]. This goal also serves to estab-
lish clear areas of responsibility for everyone involved.
Accordingly, the PC physician advises the patient, his
family and the primary treating physician but refrains
from becoming involved in decision-making regarding
disease-modifying therapies. The most basic principle
of this approach is to avoid conflicting messages and
establish a trustful relationship between the patient and
the primary physician.
The main goal of the study proposed here is to test
the feasibility of implementing a routine EPC program
into the standard oncology care of CCCs. In addition,
we are interested in 1) describing the type of supportthat patients would like from palliative care, (2) gaining
information about the effect of palliative care on patients’
QoL and healthcare costs, and (3) determining which fac-
tors could potentially ease or hinder the implementation
of EPC, respectively. The long-term goal of this project is
to create sustainable improvements in the care of patients
with incurable, life-limiting cancer.
From the perspective of health services research,
so-called “real-world” studies are urgently needed to
gather accurate information about the effects of complex
interventions (e.g. implementation of EPC) outside of
artificial study conditions [25]. To our knowledge, no
(inter‐)national study until now has investigated the
feasibility – in the sense of “putting evidence into
practice” – of the routine integration of EPC into
everyday clinical practice at CCCs.
Synergistic, relevant effects from this project have the
potential to lead to sustainable improvements in the care
of patients with life-limiting illnesses. Thus, this project
should serve as a catalyzer. Local palliative care teams
should be put in position to routinely cooperate with the
primary treating department at their respective cancer
center. In addition, this project aims at publicly raising
awareness for the need of supportive palliative care, aimed
at accompanying patients throughout their care and redu-
cing unnecessary suffering. Further, valuable information
regarding the design of future studies and improvements
in patient care can be gained from this study.
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